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Background/aim: Biochemical markers are needed to show lung involvement in COVID-19 disease. Galectin-3 is known to play a key role in
the inflammation and fibrosis process. We aimed to evaluate the predictive role of galectin-3 levels for pneumonia in patients with COVID-19.
Materials and methods: Total of 176 patients with COVID-19, confirmed with reverse transcriptase polymerase chain reaction, admitted to
the Erzurum Regional Training and Research Hospital was analyzed. The study was designed as a cross sectional. The baseline data of laboratory
examinations, including galectin-3 were collected at the time of diagnosis. CT images evaluated by a single radiologist according to the
recommendation of the Radiological Society of North America Expert Consensus Document for pulmonary involvement. The severity of
COVID-19 pneumonia was assessed using the total severity score.
Results: The mean galectin-3 level in patients with typical pneumonia was found to be significantly higher than those patients with atypical (p
< 0.01) and indeterminate appearance (p < 0.01) and patients without pneumonia (p < 0.01). The severity of lung involvement was significantly
associated with Galectin-3 levels (p < 0.01 r: 0.76). Stepwise logistic regression model showed that the levels of ferritin (odds ratio [OR] = 0.05,
p: 0.08) and galectin-3 (OR = 0.1, p < 0.01) were significantly and independently associated with typical pneumoniain COVID-19 patients.
When COVID-19 patients were evaluated in terms of typical pneumonia, we determined a cut-off value of 18.9 ng/mL for galectin-3 via ROC
analysis (87% sensitivity; 73% specificity; area under curve (AUC): 0.89; p < 0.001).
Conclusion: Galectin-3 was found as a diagnostic tool for COVID-19 associated typical pneumonia and as an indicator of both pneumonia
and its severity.
Key words: Galectin-3, covid-19, pneumonia

1. Introduction
At the end of 2019, a novel coronavirus was identified as the
cause of a series of pneumonia cases in Wuhan, a city in Hubei
Province of China. The World Health Organization (WHO)
named this disease as Coronavirus-2019 (COVID-19) [1].
COVID-19 is typically characterized by fever, dry cough,
malaise and it often manifests with pulmonary involvement.
The most common finding on computed tomography (CT)
imaging, which is the most effective method for detecting lung
abnormalities, is bilateral sub-pleural ground glass
appearance [2]. Pneumonia is observed with a frequency of
50%–75% during the disease [3]. Acute respiratory distress
syndrome (ARDS) with severe respiratory failure is seen in
17%–29% of the patients [4].
The major cause of death in COVID-19 is the aberrant
activation of the immune system called the "cytokine storm
syndrome" (CSS), which causes severe respiratory failure.
Consequently, it results in an overexpression of the
inflammatory cytokines, such as interleukin (IL)-1, tumor

necrosis factor α (TNF-α), and IL-6 from the macrophages,
monocytes, and dendritic cells [5]. Studies have shown thata
significant amount of galectin-3 is released from the
inflammatory cells in severe COVID-19 patients [6].
Galectin-3 is a carbohydrate-binding protein and it is
most highly expressed in tissue resident macrophages. It
affects several macrophage functions including efferocytosis
of apoptotic neutrophils, phagocytosis and contributes to a
pro-fibrotic macrophage phenotype by binding to the trans
membrane receptor CD98 and engaging integrins to signal via
PI3-K [7].
There is a plethora of evidence emphasizing importance of
galectin-3 in prognosis of COVID-19 disease. CSS
complicated by the development of ARDS is the major cause
of fatality in COVID-19 patients. Elevated serum levels of
galectin-3 are significantly associated with worse outcomes
and lower survival in patients suffering from ARDS[8].
Additionally, serum galectin-3 levels of patients suffering
from severe COVID-19 is significantly elevated than those
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with mild disease [9]. On a cellular level, galectin-3 was shown
to be most elevated in immune cells, responsible for initiating
CSS, during severe COVID-19 [10,11]. In addition to its effect
on inflammation, galectin-3 also plays a key role in the
development of fibrosis. In multiple models of organ fibrosis,
it has been demonstrated that galectin-3 is potently profibrotic and modulates the activity of fibroblasts and
macrophages in inflamed organs [12,13].The role of galectin3 as a mediator of lung fibrosis has long been studied since the
discovery that its levels are elevated in alveolar macrophages
following lung injury. Higher levels of galectin-3 have now
been extensively associated with the development of
restrictive lung diseases [14,15]
CT is often useful in demonstrating lung involvement in
COVID-19. Due to the dynamic nature of the disease,
exposure to radiation as a result of repeated CT scan and CT
findings that are not always associated with symptomatic
disease, there is a need for practical bedside testing to assess
disease progression. USG is used as a choice to show lung
involvement. However, its low sensitivity and specificity is an
important limitation for use. In our study, we aimed to
investigate the predictive role of galectin-3, which plays a key
role in inflammation and fibrotic processes, in pulmonary
involvement.
2. Materials and methods
2.1. Study groups
Patients older than 18 years of age tested for COVID-19 by
reverse transcriptase polymerase chain reaction (RT-PCR)
and had thorax CT after being admitted to our clinic were
considered eligible for inclusion in the study. Patients with
negative RT-PCR test results, patients without thorax CT, and
thosewho wereusingthe medication forCOVID-19 treatment
at the time of application were excluded from the study. The
control group consisted of patients with chronic diseases but
without COVID-19 clinical findings and negative RT-PCR
test andthorax CT scan results for COVID-19. Patients with a
positive RT-PCR test result for COVID-19 were evaluated for
the presence of pneumonia on a CT scan.
When COVID-19 pneumonia was detected, scoring was
performed to assess its severity. Blood samples of all study
participants were obtained on admission for the laboratory
investigations (hemogram, routine biochemistry, and level of
galectin-3). CT scan was performed within the first 24 h after
diagnosis. After the results of laboratory and imaging studies
were obtained, the relationships between the parameters of
infection, blood galectin-3 levels, and CT scan imaging of lung
involvement and severity were evaluated.
The ethics committee for clinical researches of Erzurum
Regional Training and Research Hospital approved the study
protocol (2020/21-206), and signed informed consents were
obtained from participants of the study.
2.2. Study protocol
Noncontrast thorax CT scan for all participants was
performed using a TOSHIBA AQUILLION 64 and was
evaluated by a single radiologist according to the

recommendation of the Radiological Society of North
America Expert Consensus Document for pulmonary
involvement [16]. Common imaging features of greater
specificity for COVID-19 pneumonia as typical appearance,
nonspecific imaging features of COVID-19 as indeterminate
appearance, uncommonly or not reported features of
COVID-19 as atypical, and the absence of findings suggestive
of pneumonia were reported as negative for pneumonia. The
severity of COVID-19 pneumonia was assessed using the total
severity score [17]. Each lobe in the lungs were evaluated for
the severity of the involvement and scored accordingly,
ranging between 0 and 4 points. In the scoring system, 0
points were given to the lack of involvement, while 1, 2, 3, and
4 points were given to the degrees of 1%–25%, 26%–50%,
51%–75%, and 76%–100%, respectively. The sum of the scores
from 5 lobes was considered as the total severity score.
Blood samples were collected after eight hours of fasting.
Automated biochemical and hemogram tests were performed
using the ATELLICA (Siemens) and SYSMEX XN – 1000
systems, respectively. RT-PCR testing of nasopharyngeal or
oropharyngeal swabs was performed using the Qiagen rotorgene Q system in the Department of Microbiology, Erzurum
Training and Research Hospital.
The ELISA method using the human galectin-3
PLATINUM kit (Ebioscience, Austria) was performed for
measuring the levels of galectin-3. All blood samples collected
in sodium citrate tubes were centrifuged at 1,000 g for 10 min
and stored at –80 ℃ until samples from all participants were
obtained for measuring all at once. Other laboratory
parameters were studied separately.
2.3. Statistical analysis
SPSS v: 17.0 was used for statistical analyses. Numerical
variables with normal distribution were shown as mean ± SD.
Categorical variables were presented as numbers and
percentages. Categorical variables were compared with χ2 and
Fisher's exact χ2 tests. The difference between the laboratory
results of the group with pneumonia and the control group
was evaluated by student t test. The differences between the
CT findings recommended by the Radiological Society of
North America Expert Consensus Document classification
and the galectin-3 level were evaluated by ANOVA. post-hoc
analysis was used for the differences of subgroups with each
other. Pearson's correlation analysis was used to determine
the direction and strength of the relationship between the
severity of pneumonia, galectin-3 and other inflammation
markers. Various markers that could potentially affect
patients with typical pneumonia were evaluated by creating a
single block with binary logistic analysis. The effect size of the
model was evaluated by Nagelkerke R-square. The odds ratio
was calculated for markers with potentially significant effects
on the development of pneumonia. Possible diagnostic tests
for development of typical pneumonia were evaluated with
the ROC curve. Area under curve values were calculated, in
order to determine which of the diagnostic tests are more
valuable. Sensitivity and specificity ratios for galectin-3 were
calculated.
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3. Results
The study was conducted with a total of 176 patients of which,
83 (47.2%) were male and 93 (52.8%) were female. Glucose,
creatinine, AST, ALT, D-dimer, fibrinogen, ferritin, CRP, and
galectin-3 levels were found to be higher in the patient group.
Platelet and lymphocyte counts were lower in the patient
group than that of the control group (Table 1).
When the patients are evaluated in terms of lung
involvement, no signs of pneumonia were observed in 36
(26.5%) patients. The typical findings for COVID-19
pneumonia were present in 64 (47.1%), atypical findings in 22
(16.2%), and indeterminate appearance in 14 (10.3%)
patients.
Among the comorbid diseases, 78 (44.3%) patients had
diabetes mellitus, coronary artery disease, hypertension,
asthma, and chronic obstructive pulmonary disease. Twentytwo (12.5%) patients had at least two of those diseases. The
remaining 10 (5.7%) patients had epilepsy, cerebrovascular
disease, prostate Ca, and Hashimoto thyroiditis.
Mean galectin-3 levels were found to be 44.7 ± 23.6 ng/mL
in patients with typical COVID-19 pneumonia in Thorax CT;
16.5 ± 9.5 ng/mL in those with atypical findings;15.5 ± 6.7
ng/mL in those with indeterminate appearance while in those
with no signs of pneumonia, it was found to be 15.1 ± 8.2
ng/mL (Figure 1). In the post-hoc analysis, the mean Galectin3 level in patients with typical pneumonia was found to be
significantly higher than those patients with atypical (p <
0.01) and indeterminate appearance (p < 0.01) and patients
without pneumonia (p < 0.01) (Figure 2).
The severity of lung involvement was significantly
associated with Galectin-3 levels (p < 0.01, r: 0.76), d-dimer (p
< 0.01 r: 0.44), fibrinogen (p < 0.01, r: 0.58), ferritin (p < 0.01,

r: 0.51), CRP (p < 0.01, r: 0.69), neutrophil/lymphocyte ratio
(p < 0.01, r: 0.35), lymphocyte/CRP ratio (p < 0.01 r: –0.28).
When galectin-3 level is evaluated by Radiological Society of
North America Expert Consensus Document classification,
association was also significant in patients with typical
findings (r: 0.62 p < 0.01) and with indeterminate appearance
(p < 0.01, r: 0.88). No significant relationship was found for
patients with atypical findings (p: 0.52) (Figure 3).
Stepwise logistic regression model showed that the levels
of ferritin (odds ratio [OR] = 0.005, p: 0.08) and galectin-3
(OR = 0.1, p < 0.01) were significantly and independently
associated with lung involment in COVID-19 patients (Table
2).

Table 1. Demographic and laboratory results of patients.
Patient group Control group
P value
N:136
N:40
Sex (female)
69 (50.7%)
24 (60%)
0.3
Age

62.2 ± 14.7

58.2 ± 9.3

0.1

Glucose (mg/dL)

118.8 ± 55.9

96.1 ± 15.7

0.01*

Creatinine (mg/dL)

1 ± 0.48

0.7 ± 0.2

0.07*

AST (IU/L)

41 ± 25

19.7 ± 8.8

<0.01*

ALT (IU/L)

36 ± 20

25.3 ± 13.4

0.02*

14.4 ± 1.8

14.8 ± 2.6

0.32

Platelet (K/mm )

213.2 ± 61.3

276.2 ± 52.1

<0.01*

Wbc (109/L)

6.2 ± 2.7

8.6 ± 2.6

<0.01*

Lymphocyte (mcL)

1.5 ± 0.8

2.2 ± 0.8

<0.01*

Neutrophil (mcL)

4.9 ± 6.6

5.4 ± 2.6

0.43

D-dimer (ng/mL)

861.9 ± 105.7

343.9 ± 174.8 <0.01*

Fibrinogen (mg/dL)

444.3 ± 136.1

335.2 ± 59.7

<0.01*

Ferritin (ng/mL)

321 ± 127.6

67.6 ± 56.6

<0.01*

CRP (mg/L)

30.9 ± 42.9

1.9 ± 2

<0.01*

Hemoglobin (g/dL)
3

Galectin-3 (ng/mL)
29.1 ± 21.4
15.5 ± 6.8
<0.01*
Abbreviation: AST, aspartate transaminase; ALT, alanine
transaminase; Wbc, white blood cell; CRP, C-reactive protein.
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Figure 1. CT results with galectin-3 levels (*thorax CT results
were evaluated by the recommendation of the Radiological
Society of North America Expert Consensus Document).
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Mean ratios of neutrophil/lymphocyte (NLR) (4.41 ± 5.03;
2.49 ± 2.12 p: 0.008) and lymphocyte/CRP (LCR) (1.25 ± 4.41;
3.4 ± 4.65 p: 0.03) were significantly different when compared
topatients with typical pneumonic infiltration and without

Figure 2. Galectin-3 levels and comparison of groups according
to CT results.

pneumonia. There were significant correlations between the
severity of pneumonia and NLR (r: 0.35 p < 0.01) and LCR (r:
–0.28, p < 0.01)
ROC analysis was performed to evaluate galectin-3, CRP,
and ferritin for prediction of typical pneumonia in COVID19 disease which demonstrated that area under the curve
(AUC) of galectin-3, CRP, and ferritin for predicting typical
pneumonia were 0.89 (95% Cl 0.83-94 p < 0.01); 0.85 (95% Cl
0.78–0.92 p < 0.01) and 0.79 (95% Cl 0.72–0.86 p < 0.01)
respectively. ROC analysis also demonstrated at a cut-off
value of 18.9 ng/ml for galectin-3 sensitivity and spesificity
were 87% and 73% respectively (Figure 4).
4. Discussion
Pulmonary inflammation in COVID-19 patients significantly
affects the prognosis [18]. In our study, we investigated the
relationship between lung infection and galectin-3, which has
a critical role in inflammation and fibrotic remodeling. We
found that the galectin-3 level was a good indicator of lung
infection and the severity of involvement in COVID-19
patients.
SARS-CoV-2 primarily causes acute infection in the lungs.
Subsequently, the severity of the disease is associated with
accompanying hyperinflammation, the release of proinflammatory cytokines (cytokine storm), and fibrosis. ARDS
develops in 40% of COVID-19 patients, in 20% of which is
severe [15]. Galectin 3 is thought to exacerbate inflammation
by accumulating macrophages in the lungs, thus, playing a key
role in the development of cytokine storm [18]. Zhiheng et al.

Figure 3. Correlation analysis between CT score galectin-3, CRP, D- dimer, and ferritin.
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[8] found that the levels of galectin-3 in ARDS patients were
high and closely related to the severity of the disease. ARDS is
a process that intertwines with fibrosis. High galectin-3 levels
have been shown to impair gas exchange and remain high
even in the early stages of fibrosis [19]. In other studies,
galectin-3 levels were found to be associated with the
development of cardiac and renal fibrosis, long
hospitalization periods, and mortality [12,13]. In idiopathic
pulmonary fibrosis, galectin-3 level was found to be higher in
bronchial secretions (BALF) obtained from those patients
with the active disease than those with the stable disease. High
levels of galectin-3 had been observed to regress after steroid
therapy [14].
The diagnosis and the follow-up of lung infection are
important in patients with COVID-19. The sensitivity of CT
imaging in the diagnosis of COVID-19 disease ranges from
60% to 98% while the specificity ranges between 25% and 53%.
In addition to the higher sensitivity compared to the
sensitivity of RT-PCR in COVID-19 diagnosis, CT provides
Table 2. Significant predictors of pneumonia in COVID-19 disease
in multivariable logistic regression analysis.
OR
95%Cl lower-upper
P value
Galectin-3

0.1

1.04–1.17

0.01

Ferritin

0.05

1.00–1.01

0.08

2

Nagelkerke R : 0.51 p < 0.01.
Abbreviation: Cl, confidence interval, d-dimer, CRP, WBC,
galectin-3, ferritin, age, and sex were included in stepwise
regression analysis as probable predictors.

Figure 4. ROC curve for galectin-3, CRP, and ferritin in the
diagnosis of typical pneumonia.
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information about the progression of the disease [20,21].
Lung infection observed in CT imaging studies does not
always relate to the symptomatic disease. Supporting these
findings, Hu et al. [22] reported that 70.8% of RT-PCR
positive asymptomatic patients had abnormalities in CT scan.
Inui et al. [23] observed 44/82 (54%) CT scan abnormalities
in 112 asymptomatic and RT-PCR positive patients in the
“Diamond Princess” cruise ship. Although typical CT image
related to COVID-19is often the bilateral peripheral “groundglass” opacity, atypical presentations such as hilar
consolidation or pleural thickening are also encountered. In
order to standardize the findings, various consensus reports
have been prepared regarding the CT findings frequently
observed during the course of COVID-19 [16,24]. Fang et al.
[25] reported the typical and atypical CT features in 78% and
28% of the patients, respectively. Tao et al. [21] observed
typical COVID-19 pulmonary features in 60% of the patients.
In our study, we detected the typical, indeterminate, and
atypical CT findings in 64%, 14%, and 22% of the patients
diagnosed by RT-PCR.
Although CT imaging is a highly sensitive method, its
specificity is low; for instance,similar findings forpneumonia
caused by influenza, cytomegalovirus, and miscellaneous
agents of atypical pneumonia result in diagnostic difficulties
[26]. Another disadvantage of CT imaging for the patient is
the exposure to radiation. In particular, more than a single CT
scan sessionis required in case of ambivalent results as well as
evaluating the prognosis. Although thorax USG can easily be
performed at the bedside of the patient and repeated when
necessary, the low sensitivity and specificity limit its use in
diagnosis and follow-up [20,24]. It is obvious that a rapid and
practical procedure is needed to demonstrate the lung
infection in COVID-19 patients. As a result of our study, we
suspect that galectin-3 levels could be used asan indicator of
lung infection (cut-off value: 18.9 ng/mL [0.83–0.94];
sensitivity: 87%; specificity 73%; AUC: 0.89; p < 0.001)
Various studies that have suggested the severity of the
COVID-19 varied with gender revealed that male patients had
been affected more severely [27,28]. In our study, we did not
observe a gender difference in neither the CT score nor the
Galectin-3 levels.
High levels of IL-6, CRP, LDH, AST, WBC and notrophil
count are associated with respiratory failure in COVID-19
disease [29,30]. Among these markers, harold et al. [29]
emphasized that high IL-6 and crp values were an important
indicator to show the need for a mechanical
ventilator.Although we did not evaluate respiratory failure
with blood gas analysis in our study, it was observed that ddimer, fibrinogen, lymphocytes, ferritin, CRP, NLR, LCR,
galectin-3 and AST values were correlated with CT score.
Similarly to our results tan et al. [31] reported that CRP
(r = 0.62, p <
0.01),
granulocyte/lymphocyte
ratio
(r = 0.49, p < 0.01) and the number of lymphocytes (r = –0.37;
p < 0.01) were associated with CT severity score and they
observed CRP was found to be significantly increased in the
initial phases of the infection for severe COVID-19 patients.
We observed the strongest association with CT severity score
was high levels of galectin-3 (r: 0.76 p < 0.01) followed by CRP
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(r: 0.69 p < 0.01), and ferritin (r: 0.51 p < 0.01).When patients
with typical appearance in ct scan were evaluated, this
association was also significant for galectin (r: 0.74 p < 0.01),
CRP (r: 0.50 p < 0.01) and ferritin (r: 0.27 p: 0.02).
Today, the severity of COVID-19 is best evaluated with
CT.It is important to predict the severity of the disease in
order to reduce mortality with an effective treatment.Many
biomarkers have been studied for this purpose. Among these,
CRP, erythrocyte sedimentation rate, IL-6, ferritin,
procalcitonin and d-dimer are the most frequently studied
[32,33]. Presence of pneumonia provides important
information about the prognosis of the disease. In our study,
when ROC analysis was performed to predict typical
pneumonia for galectin-3, CRP and ferritin, AUC values were
0.89 (95% Cl 0.83–94); 0.85 (95% Cl 0.78–0.92), and 0.79 (95%
Cl 0.72–0.86), respectively.
Our study had several limitations. The most important of
these is the lack of follow-up for CT scan images in the
patients. CT scans in the early period in COVID-19 may not
show abnormalities. High galectin-3 levels were detected in
patients in whom no signs of pneumonia were detected,
possibly due to the early stage of the disease. We consider that
the sensitivity of Galectin-3 levels for indicating lung
involvement in the disease would increase when the patients
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